Lunai Bioworks , an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved ...

Abbott and Exact Sciences today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving ...

Q3 2025 Earnings Call November 20, 2025 4:30 PM ESTCompany ParticipantsTony DammicciChristopher Marlett - Co-Founder, ...

Lawyer Petchie Rose Espera has broken her silence to denounce what she calls a “deeply alarming” pattern of falsification ...

Explains the major reforms introduced by the four Labour Codes, detailing new wage rules, social security expansion, safety standards, and transitional compliance ...

Once you lose customer trust, it is incredibly difficult to win back. Breaches fundamentally erode your reputation in ways ...

The B2B leaders outperforming peers in ROI aren't collecting more data; they're building smarter, connected ecosystems where ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult ...

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings off ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share. Click here ...

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026More than 21 ...

For the nine months ended September 30, 2025, CureVac recorded revenues of €43.3 million from GSK, €11.1 million from BioNTech, and €1.8 million from CRISPR Therapeutics, compared with €508.3 million, ...